Menus Subscribe Search

Genes Are Us


Elizabeth Taylor in Cleopatra. (Photo: Wikimedia Commons)

Elizabeth Taylor, My Great-Grandpa, and the Future of Antibiotics

• June 27, 2014 • 4:00 AM

Elizabeth Taylor in Cleopatra. (Photo: Wikimedia Commons)

While it’s not clear whether or not they worked for the Cleopatra star over a half-century ago, phage treatments could help solve the growing problem of antibiotic resistance.

In March of 1961, Elizabeth Taylor was in London filming her next blockbuster, Cleopatra, when she fell ill with pneumonia. She underwent an emergency tracheotomy, and for days the press followed every development in her increasingly dire situation. On March 7, a Philadelphia-area newspaper reported that a local company, Delmont Laboratories, had put several doses of an unusual antibacterial treatment on the next jet to London at the request of Taylor’s doctors. With a touch of community pride, the paper reported that the treatment, “staphylococcus bacteriophage lysate,” was exclusively manufactured by Delmont Laboratories, and that “Christopher Roos, laboratory director and formerly senior bacteriologist for Sharpe and Dohme, played a major part in its development.”

It’s not clear what impact the treatment had on Elizabeth Taylor, but Christopher Roos, my great-grandfather, didn’t doubt its efficacy. My mother recalls that during her childhood visits to his house, he would treat her colds with a dose, administered as a nasal spray. Staphylococcus bacteriophage lysate is a form of antibacterial therapy based on phages, viruses that are the natural predators of bacteria. Discovered early in the 20th century, decades before modern antibiotics, phages have an obvious therapeutic potential that doctors and scientists were quick to explore. In the 1930s and ’40s, bacteriophage preparations were manufactured by major drug companies like Eli Lilly, and used to treat everything from cholera to wound infections.

Aside from the technological advances, there is now a major medical and economic reason to reconsider phages: the growing crisis of antibiotic resistance. The number of antibiotic-resistant bacterial infections is growing rapidly, while the drug pipeline of new antibiotics is drying up.

But the hype got a bit ahead of the science. The biology of these viruses was not well understood, and phage treatments were difficult to prepare consistently. The effectiveness of the treatments varied widely, and while there were some clinical studies of phage therapy, many weren’t particularly rigorous by rapidly modernizing, post-World War II standards. In the mid-1940s, penicillin, cheap and obviously effective, began to be mass-produced in the U.S. By the time that Liz Taylor’s doctors called my great-grandfather, phage therapy was on the wane. Knowing that, the story sounds like the familiar scenario of the celebrity doctor who peddles some unproven alternative treatment to his famous patient.

But that characterization isn’t accurate. Despite the lack of rigor in the early studies, there is a long record of substantial evidence showing that phage therapy holds genuine promise. After phage therapy was superseded by antibiotics in the West, researchers in the Soviet Union and Eastern Europe—where antibiotics weren’t as readily available—continued to work on phage therapy, with encouraging results. Some occasional studies continued in the U.S. and Western Europe as well. And now, phage therapy is in the limelight again, drawing the interest of researchers, governments, and biotech companies.

What changed? As my Washington University colleague Jeffrey Gordon and his co-workers wrote, we’re experiencing “the incipient rise of a phage biology renaissance,” thanks to modern DNA analysis technologies. Discovered before we knew that genes were made of DNA, we now know that phages are highly efficient gene-delivery machines. They inject their genomes into bacteria, hijack the bacterial machinery to make new DNA copies of themselves, and repackage those copies into protein capsules, bursting open the bacterial cell in the process. The capsules then diffuse away in search of new bacterial prey. By scouring oceans, soil, and our own bodies for phage DNA, researchers have discovered an enormous world of viruses with a tremendous bacterial-killing capability—according to one review, “phage predation destroys an estimated half of the world bacteria population every 48 hours.” The diversity of the world’s bacteriophages is an essentially inexhaustible source that we can trawl for potential anti-bacterial treatments, with the aid of today’s highly effective biotechnological tools. And researchers like Gordon and his lab members are exploring how phages operate in their natural habitats, such as the human gut.

Aside from the technological advances, there is now a major medical and economic reason to reconsider phages: the growing crisis of antibiotic resistance. As the Centers for Disease Control reported last year, the number of antibiotic-resistant bacterial infections is growing rapidly, while the drug pipeline of new antibiotics is drying up. Two million people acquire antibiotic-resistant infections each year in the U.S., leading to over $20 billion in health care costs. And antibiotics themselves pose a major burden, accounting for 20 percent of all emergency room visits for adverse drug events.

Phage therapy has the potential to avoid all of these problems. While bacteria can become resistant to any one strain of phage, there are many different phage strains out there that could be combined into an effective, multi-strain cocktail treatment. And unlike chemical antibiotics, phages have their own genomes that can evolve to circumvent the defenses of resistant bacteria. Phage therapy also would not destroy the important community of healthy bacteria in our guts. Antibiotics wipe out these healthy gut bacteria, leaving people vulnerable to opportunistic infections by Clostridium difficile, a bacteria that the CDC reports is responsible for 14,000 deaths each year in the U.S.

The need is there, but will phage therapy actually work in humans? The answer is a cautious yes. The biomedical research community is certainly ready to try, bringing new funding, technology, and rigor to this old-fashioned approach to infections. A clinical trial of phage therapy for infected burn wounds is underway in Europe. The FDA has already approved phages to kill contaminating bacteria in food, and phage treatments for infections are being tested for efficacy in some animal studies, as well as for safety in a few human studies (PDF). Phage therapy may or may not become the major solution to our crisis of antibiotic resistance, but it is very likely that we’ll soon see a variety of limited but successful applications of phage therapy in humans.

Delmont’s product was a federally-approved drug in the 1950s, but as the FDA revised its approach to regulation in later decades, the small company struggled (PDF), and, in the 1990s, it stopped selling its bacteriophage treatments for human use. The company continues to make a USDA-licensed phage therapy to treat recalcitrant skin infections in dogs. When my great-grandfather sent those doses of phage lysate express to Liz Taylor, the time wasn’t quite right for phage therapy, scientifically or economically. But times have changed, and this old-fashioned treatment may become cutting-edge.

Michael White
Michael White is a systems biologist at the Department of Genetics and the Center for Genome Sciences and Systems Biology at the Washington University School of Medicine in St. Louis, where he studies how DNA encodes information for gene regulation. He co-founded the online science pub The Finch and Pea. Follow him on Twitter @genologos.

More From Michael White

A weekly roundup of the best of Pacific Standard and, delivered straight to your inbox.

Recent Posts

August 20 • 4:00 AM

Of Course I Behaved Like a Jerk, I Was Just Watching ‘Jersey Shore’

Researchers find watching certain types of reality TV can make viewers more aggressive.

August 20 • 2:00 AM

Concluding Remarks About Housing Affordability and Supply Restricitions

Demand, not supply, plays the dominant role in explaining the housing affordability crisis. The wages are just too damn low.

August 19 • 4:00 PM

Can Lawmakers Only Make Laws That Corporations Allow?

There’s a telling detail in a recent story about efforts to close loopholes in corporate tax laws.

August 19 • 12:00 PM

How ‘Contagion’ Became Contagious

Do ideas and emotions really spread like a virus?

August 19 • 10:00 AM

Child Refugees: The New Barbarians

The disturbing rhetoric around the recent rise in child refugees into the United States from Central America may be shaping popular opinion on upcoming immigration reform.

August 19 • 8:00 AM

Making Police Departments More Diverse Isn’t Enough

Local police departments should reflect the communities they serve, but fixing that alone won’t curb unnecessary violence.

August 19 • 7:15 AM

Common Knowledge Makes Us More Cooperative

People are more inclined to take mutually beneficial risks if they know what others know.

August 19 • 6:00 AM

Seeking a Healthy Public School Lunch? Good Luck

Mystery meat will always win.

August 19 • 4:00 AM

The Positive Effects of Sports-Themed Video Games

New research finds sports-themed video games actually encourage some kids to get onto the field.

August 19 • 1:00 AM

DIY Diagnosis: How an Extreme Athlete Uncovered Her Genetic Flaw

When Kim Goodsell discovered that she had two extremely rare genetic diseases, she taught herself genetics to help find out why.

August 18 • 3:30 PM

Mister Rogers’ Heart-Healthy Neighborhood

Researchers find living in a friendly, cohesive neighborhood lowers seniors’ chances of having a heart attack.

August 18 • 2:00 PM

Wealth or Good Parenting?

Framing the privileges of the rich.

August 18 • 12:00 PM

How Much Did the Stigma of Mental Illness Harm Robin Williams?

Addiction treatment routinely fails people with mental illnesses, while mental health care often ignores addiction. And everywhere, stigma is rife. Can a tragic death prompt a more intelligent approach?

August 18 • 10:00 AM

Punished for Being Poor: The Problem With Using Big Data in the Justice System

Correctional departments use data-driven analyses because they’re easier and cheaper than individual assessments. But at what cost?

August 18 • 8:00 AM

What Americans Can Learn From a Vial of Tibetan Spit

Living high in the mountains for thousands of years, Tibetans have developed distinct biological traits that could benefit all of us, but translating medical science across cultures is always a tricky business.

August 18 • 6:00 AM

The Problems With William Deresiewicz’s New Manifesto

Excellent Sheep: a facile approach to an urgent critique.

August 18 • 4:00 AM

Ferguson Is a Serious Outlier

One black city council member is not nearly enough. In a study of city councils, only one place in America had a greater representational disparity than Ferguson, Missouri.

August 16 • 4:00 AM

Six Days in Ferguson: Voices From the Protests

A day-by-day chronology of what happened in Ferguson, drawn from the best reporting by journalists and witnesses on the ground.

August 15 • 4:00 PM

Skirting Ochobo: Big Business Finds a Way Around Local Customs

The “liberation wrapper,” which was designed to shield mouths from public view while eating, has helped a Japanese chain increase sales by over 200 percent.

August 15 • 2:00 PM

How Wall Street Tobacco Deals Left States With Billions in Toxic Debt

Politicians wanted upfront cash from a legal victory over Big Tobacco, and bankers happily obliged. The price? A handful of states promised to repay $64 billion on just $3 billion advanced.

August 15 • 12:00 PM

How the Sexes Evolved

The distinction between males and females is one of the oldest facts of biology—but how did it come to affect our social identity?

Follow us

Common Knowledge Makes Us More Cooperative

People are more inclined to take mutually beneficial risks if they know what others know.

How a Shift in Human Head Shape Changed Everything

When did homo sapiens become a more sophisticated species? Not until our skulls underwent "feminization."

Journalists Can Get PTSD Without Leaving Their Desks

Dealing with violent content takes a heavy toll on some reporters.

Do Ticking Clocks Make Women More Anxious to Have Children?

Yes, but apparently only women who grew up poor.

Facebook App Shoppers Do What Their Friends Do

People on Facebook are more influenced by their immediate community than by popular opinion.

The Big One

One in two full-time American fast-food workers' families are enrolled in public assistance programs, at a cost of $7 billion per year. July/August 2014 fast-food-big-one
Subscribe Now

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.